{"transactions":[{"id":1596200,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-05T21:10:07.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":41316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":41316,"derivative":{"exercise_price":32.66,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":41316},"source":{"system":"sec-edgar","filing":"0000950170-24-025901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025901/ownership.xml","form_type":"4"}},{"id":1596199,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:10:07.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":28628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":69213,"source":{"system":"sec-edgar","filing":"0000950170-24-025901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025901/ownership.xml","form_type":"4"}},{"id":1685482,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-05T21:49:15.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":5365,"price":29.46,"value":158052.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":40585,"source":{"system":"sec-edgar","filing":"0000950170-24-002511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024002511/ownership.xml","form_type":"4"}},{"id":1692429,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T22:28:42.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":3064,"derivative":{"exercise_date":"2024-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3062},"source":{"system":"sec-edgar","filing":"0000950170-24-001173","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024001173/ownership.xml","form_type":"4"}},{"id":1692428,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-03T22:28:42.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":45950,"source":{"system":"sec-edgar","filing":"0000950170-24-001173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024001173/ownership.xml","form_type":"4"}},{"id":1973480,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T22:20:41.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":38834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":38834,"derivative":{"exercise_price":40.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":38834},"source":{"system":"sec-edgar","filing":"0001209191-23-015776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015776/doc4.xml","form_type":"4"}},{"id":1973479,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T22:20:41.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":27484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":42888,"source":{"system":"sec-edgar","filing":"0001209191-23-015776","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015776/doc4.xml","form_type":"4"}},{"id":2060424,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:23:40.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":2427,"price":37.21,"value":90308.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023."}],"balance_after":15404,"source":{"system":"sec-edgar","filing":"0001209191-23-002414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123002414/doc4.xml","form_type":"4"}},{"id":2067632,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-01-05T01:29:37.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":3062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":6126,"derivative":{"exercise_date":"2023-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3062},"source":{"system":"sec-edgar","filing":"0001209191-23-001490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123001490/doc4.xml","form_type":"4"}},{"id":2067631,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-05T01:29:37.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":3062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":17831,"source":{"system":"sec-edgar","filing":"0001209191-23-001490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123001490/doc4.xml","form_type":"4"}},{"id":2350334,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-05T02:04:17.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":18600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 12,720."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 12,720."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 12,720."}],"balance_after":18600,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0001209191-22-016535","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016535/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-03"}},{"id":2354421,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T00:38:35.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":12720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":12720,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":12720},"source":{"system":"sec-edgar","filing":"0001209191-22-015917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122015917/doc4.xml","form_type":"4"}},{"id":2354420,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-03-04T00:38:35.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":3062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":9188,"derivative":{"exercise_date":"2022-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3062},"source":{"system":"sec-edgar","filing":"0001209191-22-015917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122015917/doc4.xml","form_type":"4"}},{"id":2354419,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:38:35.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":12720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":14769,"source":{"system":"sec-edgar","filing":"0001209191-22-015917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122015917/doc4.xml","form_type":"4"}},{"id":2354418,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:38:35.000Z","date":"2022-01-01","kind":"sale","acquired":false,"shares":1013,"price":112.24,"value":113699.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022."}],"balance_after":2049,"source":{"system":"sec-edgar","filing":"0001209191-22-015917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122015917/doc4.xml","form_type":"4"}},{"id":2354417,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:38:35.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":3062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":3062,"source":{"system":"sec-edgar","filing":"0001209191-22-015917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122015917/doc4.xml","form_type":"4"}},{"id":2574795,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-09T21:38:46.000Z","date":"2021-09-07","kind":"exercise","acquired":false,"shares":3482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of September 7, 2021."}],"balance_after":12451,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":3482},"source":{"system":"sec-edgar","filing":"0001209191-21-055347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121055347/doc4.xml","form_type":"4"}},{"id":2574794,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-09T21:38:46.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":3482,"price":180.12,"value":627177.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 7, 2021 at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-055347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121055347/doc4.xml","form_type":"4"}},{"id":2574793,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-09T21:38:46.000Z","date":"2021-09-07","kind":"exercise","acquired":true,"shares":3482,"price":14.58,"value":50767.56,"ownership":{"direct":true},"balance_after":3482,"source":{"system":"sec-edgar","filing":"0001209191-21-055347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121055347/doc4.xml","form_type":"4"}},{"id":2583554,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-31","kind":"exercise","acquired":false,"shares":1817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of August 31, 2021."}],"balance_after":15933,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":1817},"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583553,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-31","kind":"exercise","acquired":false,"shares":22983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 31, 2021."}],"balance_after":41817,"derivative":{"exercise_price":19.27,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":22983},"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583552,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 30, 2021."}],"balance_after":64800,"derivative":{"exercise_price":19.27,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583551,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-31","kind":"sale","acquired":false,"shares":24800,"price":160.22,"value":3973456.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.59, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2021 at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583550,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-31","kind":"exercise","acquired":true,"shares":1817,"price":14.58,"value":26491.86,"ownership":{"direct":true},"balance_after":24800,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583549,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-31","kind":"exercise","acquired":true,"shares":22983,"price":19.27,"value":442882.41,"ownership":{"direct":true},"balance_after":22983,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583548,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":300,"price":160.84,"value":48252.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.61 to $160.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583547,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":300,"price":159.53,"value":47859.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $159.79, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":300,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583546,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":300,"price":158.42,"value":47526.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.08 to $158.81, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583545,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":496,"price":157.33,"value":78035.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.86 to $157.84, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":900,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583544,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":300,"price":156.1,"value":46830.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.81 to $156.30, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":1396,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583543,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":1700,"price":155.29,"value":263993.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.805 to $155.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":1696,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583542,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":1100,"price":154.29,"value":169719.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.76 to $154.71, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":3396,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583541,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":704,"price":153.22,"value":107866.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.75 to $153.62, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":4496,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2583540,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:30:44.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":5200,"price":19.27,"value":100204.0,"ownership":{"direct":true},"balance_after":5200,"source":{"system":"sec-edgar","filing":"0001209191-21-054315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054315/doc4.xml","form_type":"4"}},{"id":2611480,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-06T22:17:21.000Z","date":"2021-08-05","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 61,875 shares as of August 5, 2021."}],"balance_after":70000,"derivative":{"exercise_price":19.27,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-050225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121050225/doc4.xml","form_type":"4"}},{"id":2611479,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:17:21.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":530,"price":152.13,"value":80628.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.01 to $152.38, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-050225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121050225/doc4.xml","form_type":"4"}},{"id":2611478,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:17:21.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":9568,"price":151.41,"value":1448690.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.015 to $151.99, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price."}],"balance_after":530,"source":{"system":"sec-edgar","filing":"0001209191-21-050225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121050225/doc4.xml","form_type":"4"}},{"id":2611477,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:17:21.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":9902,"price":150.65,"value":1491736.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.01 to $151.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price."}],"balance_after":10098,"source":{"system":"sec-edgar","filing":"0001209191-21-050225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121050225/doc4.xml","form_type":"4"}},{"id":2611476,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:17:21.000Z","date":"2021-08-05","kind":"exercise","acquired":true,"shares":20000,"price":19.27,"value":385400.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-21-050225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121050225/doc4.xml","form_type":"4"}},{"id":2806247,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T22:49:05.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":12250,"derivative":{"underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-018321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121018321/doc4.xml","form_type":"4"}},{"id":2806246,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T22:49:05.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":73500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 73,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":73500,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":73500},"source":{"system":"sec-edgar","filing":"0001209191-21-018321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121018321/doc4.xml","form_type":"4"}},{"id":3227563,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T22:28:08.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":125000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-20-006975","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000089924320006975/doc4.xml","form_type":"4"}},{"id":3723507,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-20T21:16:44.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":17750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 18, 2018 with respect to 17,750 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":17750,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":17750},"source":{"system":"sec-edgar","filing":"0001209191-18-063657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919118063657/doc4.xml","form_type":"4"}},{"id":3723506,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-20T21:15:48.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on November 1, 2018 with respect to 90,000 shares of Common Stock, with 25% vesting on November 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":90000,"derivative":{"exercise_price":19.27,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-18-031474","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000089924318031474/doc4a.xml","form_type":"4/A","original_submission_date":"2018-11-01"}},{"id":3778131,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":93481,"kind":"person","name":"Goddard Glenn","position":1,"cik":"0001581992","reported_name":"Goddard Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-01T22:37:10.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on November 1, 2018 with respect to 90,000 shares of Common Stock, with 25% vesting on November 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":90000,"derivative":{"exercise_price":19.27,"expiration_date":"2018-10-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-18-027919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000089924318027919/doc4.xml","form_type":"4"}}]}